AbbVie Aktie
WKN DE: A1J84E / ISIN: US00287Y1091
|
06.01.2026 13:17:03
|
AbbVie: Health Canada Approves MAVIRET
(RTTNews) - AbbVie (ABBV) announced that Health Canada has approved MAVIRET for the treatment of acute and chronic hepatitis C virus infection in adults and pediatric patients 3 years of age and older and weighing = 12 kg. The company noted that Canadian healthcare providers are now empowered to start treatment for acute HCV as soon as the diagnosis is made.
MAVIRET is a pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, dosed once-daily as three oral tablets.
For More Such Health News, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AbbVie Inc
Analysen zu AbbVie Inc
Aktien in diesem Artikel
| AbbVie Inc | 182,95 | -1,98% |
|